FT3 - FREE TRIIODOTHYRONINE
Report
- Report Number
- 1823260-2015-04176
- Event Type
- Malfunction
- Date Received
- September 16, 2015
- Date of Event
- September 2, 2015
- Report Date
- September 30, 2015
- Manufacturer
- ROCHE DIAGNOSTICS
- Product Code
- CDP
- PMA / PMN Number
- K963127
- Removal / Correction Number
- NA
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- JA
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
THE SAMPLE WAS SUBMITTED FOR INVESTIGATION. INVESTIGATION CONFIRMED THE PRESENCE OF A STREPTAVIDIN INTERFERING FACTOR. THIS SPECIFIC INTERFERENCE IS ADDRESSED IN PRODUCT LABELING.
THIS EVENT OCCURRED IN (B)(6).
THE CUSTOMER QUESTIONED RESULTS FROM 1 PATIENT SAMPLE TESTED FOR THYROTROPIN (TSH), FREE THYROXINE (FT4) AND FREE TRIIODOTHYRONINE (FT3). THE CUSTOMER PROVIDED THE SAMPLE FOR INVESTIGATION. OF THE DATA PROVIDED, ERRONEOUS FT4 AND FT3 RESULTS WERE IDENTIFIED BETWEEN THE CUSTOMER'S E601 ANALYZER, AN ARCHITECT ANALYZER, AN E 170 ANALYZER USED AT THE INVESTIGATION SITE AND AN E411 ANALYZER USED AT THE INVESTIGATION SITE. IT IS NOT KNOWN IF ERRONEOUS RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. THIS MEDWATCH WILL COVER FT3. REFER TO MEDWATCH WITH PATIENT IDENTIFIER (B)(6) FOR INFORMATION ON THE FT4 ERRONEOUS RESULTS. REFER TO THE ATTACHED DATA FOR PATIENT RESULTS. NO ADVERSE EVENT WAS REPORTED. THE E 170 ANALYZER SERIAL NUMBER WAS (B)(4). THE E411 ANALYZER SERIAL NUMBER WAS (B)(4). THE FT3 REAGENT LOT NUMBER USED WITH THE E 170 ANALYZER AT THE INVESTIGATION SITE WAS 185694 WITH AN EXPIRATION DATE OF 05/31/2016. THE FT3 REAGENT LOT NUMBER USED WITH THE E411 ANALYZER AT THE INVESTIGATION SITE WAS 183221 WITH AN EXPIRATION DATE OF 01/31/2016. THE SERIAL NUMBER FOR THE CUSTOMER'S E601 ANALYZER WAS (B)(4).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 613987 | FT3 - FREE TRIIODOTHYRONINE | RADIOIMMUNOASSAY, TOTAL TRIIODOTHYRONINE | CDP | ROCHE DIAGNOSTICS | NA | ASKU |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 064 YR |